Evofem Biosciences Faces Delisting Concerns
Ticker: EVFM · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1618835
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Evofem might get kicked off the exchange - big trouble.
AI Summary
Evofem Biosciences, Inc. filed an 8-K on January 10, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was January 6, 2025. The company, formerly known as Neothetics, Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates potential issues with Evofem Biosciences' continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a severe risk to investors.
Key Numbers
- 001-36754 — SEC File Number (Identifies the company's filing with the SEC.)
- 20-8527075 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- Neothetics, Inc. (company) — Former company name
- January 6, 2025 (date) — Earliest event date
- January 10, 2025 (date) — Filing date
- San Diego, California (location) — Principal executive offices
FAQ
What specific listing rule or standard has Evofem Biosciences failed to satisfy?
The filing does not specify the exact rule or standard that Evofem Biosciences has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the earliest date of the event reported in this 8-K?
The earliest event reported in this 8-K is January 6, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 10, 2025.
What was Evofem Biosciences, Inc. formerly known as?
Evofem Biosciences, Inc. was formerly known as Neothetics, Inc.
Where are Evofem Biosciences, Inc.'s principal executive offices located?
Evofem Biosciences, Inc.'s principal executive offices are located at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
Filing Stats: 799 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2025-01-10 16:05:26
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $0.01 — or the Company's common stock was below $0.01 per share for 30 consecutive calendar d
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-25-001682.txt ( ) — 208KB
- evfm-20250106.xsd (EX-101.SCH) — 3KB
- evfm-20250106_lab.xml (EX-101.LAB) — 33KB
- evfm-20250106_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: January 10, 2025 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer